The global obesity issue is bursting at the seams. According to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults were overweight, as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweight in 2016, as well. It’s an issue that’s been plaguing society for quite some time. Fortunately, some believe psilocybin may be the key to resolving the obesity epidemic, which could fuel upside for companies such as NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Tryp Therapeutics Inc. (CSE:TRYP), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), and Compass Pathways (NASDAQ:CMPS).
In fact, according to a Pharmacy Times interview, Clive Ward Able, MD, BPharm, president of Clintell, consultant to NeonMind Inc, and a trained pharmacist and physician, he “noted that the use of psychedelic medicine to treat obesity has 2 potential mechanisms of approach. The first is by giving a psychedelic compound as part of psychotherapy, such as psilocybin, at a psychedelic dose—this approach is called drug-enhanced psychotherapy. At this dose, it works as an agonist against serotonergic receptors, and, specifically, the 5-HT2A receptors.”
“What that does is it gives you the psychedelic event, which seems to be able to help along with psychotherapy,” Ward Able said, as quoted by Pharmacy Times. “Secondly, it also has effects on the 5-HT2C receptors, which are very much related to satiety or hunger and the control of hunger. So there, we can look at a different formulation where we use a much lower dose, probably 10% to 15% of what would normally be used for a psychedelic dose, but you do that on a daily or 4 times a week dosing.”